Understanding how a modified poliovirus fights cancer
Resolving Spatiotemporal Dynamics of Recombinant Poliovirus Immunotherapy
This research explores how a specially modified poliovirus can help your body's immune system find and destroy cancer cells.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11117067 on NIH RePORTER |
What this research studies
Our bodies have special immune cells called dendritic cells (cDC1s) that are crucial for teaching the immune system to recognize and attack cancer. However, these cells are scarce, difficult to activate, and often suppressed by the tumor itself. This project is exploring a modified poliovirus, called PVSRIPO, which naturally targets these important dendritic cells. When the virus infects these cells, it triggers a strong immune signal that helps activate other immune cells, like T cells, to fight the cancer.
Who could benefit from this research
Good fit: Patients with certain types of cancer that might respond to immunotherapy, particularly those where dendritic cell activation is beneficial, could be ideal candidates.
Not a fit: Patients whose cancers do not respond to immune-based therapies or who have conditions that prevent safe administration of viral therapies may not benefit.
Why it matters
Potential benefit: If successful, this could lead to new immunotherapy options for cancer patients by enhancing the body's natural defenses.
How similar studies have performed: Previous work has shown promising immune activation with this modified poliovirus in laboratory settings, suggesting a foundation for this deeper investigation.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Gromeier, Matthias — Duke University
- Study coordinator: Gromeier, Matthias
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.